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AbstrACt
Objective The aim of this study was to examine long-term 
trends in the receipt of medicines information (MI) among 
adult medicine users from 1999 to 2014.
Design Repeated cross-sectional postal survey from the 
years 1999, 2002, 2005 and 2008–2014.
setting Each study year, a new nationally representative 
sample of 5000 Finns aged 15–64 years was drawn from 
the Population Register Centre of Finland.
Participants The range of annual respondents varied 
from 2545 to 3371 and response rates from 53% to 
67%. Of the total responses (n=29 465), 64% were from 
medicine users (n=18 862, ranging by year from 58% to 
68%).
Outcome measures Receipt of information on medicines 
in use within 12 months prior to the survey from a given 
list of consumer MI sources available in Finland.
results Physicians, community pharmacists and package 
leaflets were the most common MI sources throughout 
the study period. Receipt of MI increased most from 
the Internet (from 1% in 1999 to 16% in 2014), while 
decreased most from physicians (62% to 47%) and 
package leaflets (44% to 34%), and remained stable from 
community pharmacists (46% to 45%) and nurses (14% 
to 14%). In 1999, of the medicine users 4% did not report 
receipt of MI from any of the sources listed in the survey, 
while this proportion had remarkably increased to 28% in 
2014.
Conclusions Healthcare professionals and package 
leaflets had still a dominating importance in 2014 despite 
the growing number of MI sources over time, but still a 
minority of adult medicine users reported receiving MI 
via the Internet in 2014. Worrying is that the proportion of 
adult medicine users who did not receive MI from any of 
the sources became seven fold during the study period.
IntrODuCtIOn
Consumer access to medicines informa-
tion (MI) has dramatically improved during 
the last decades.1–7 Driving forces for more 
open access to MI have been drug safety 
issues, patients’ right to know about medic-
inal interventions that they are exposed to 
and tendency to empower people in taking 
more responsibility for self-management of 
their diseases.2 4 7 These changes have led to 
improved availability of MI, first on paper 
and later via the Internet and electronic 
applications in smartphones and other elec-
tronic devices. The applications are evolving 
fast towards systems enabling customised MI, 
interactive communications and following 
up treatments.1 3 4 8–10 Improved communica-
tion on medications has also been a strategic 
priority in national and international medi-
cines policies, for example, within the Euro-
pean Union.2 4 11–16 
Consumers’ health information seeking, 
including MI seeking from various informa-
tion sources, has been widely researched.17–20 
Previous research on the receipt of MI among 
the adult population have either (1) focused 
on particular patient groups such as asth-
matics,21 people with cancer,22 cardiovascular 
diseases,23 HIV/AIDS,24 mental disorders25 or 
strengths and limitations of this study
 ► The key strength of this national population study is 
that it examines trends in the receipt of medicines 
information (MI) among adult medicine users within 
a 15-year time period by using representative ran-
dom population samples with high enough response 
rates for generalisable results.
 ► Repeated surveys are necessary to indicate popu-
lation level changes in the utilisation of available MI 
sources and reveal needs to develop MI practices 
and policies at the national level.
 ► Due to the cross-sectional method without cohorts, 
it is not possible to follow-up changes in the receipt 
of MI over time at the individual level.
 ► The data did not provide any information about the 
quality, validity or amount of the MI received.
 ► Factors contributing to a growing number of adult 
medicine users not receiving MI from any sources 
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vasculitis26 and pregnant women,27 28 or (2) focused on 
certain medicine user groups such as users of hormone 
replacement therapies,29–31 analgesics,32 33 antidepres-
sants,34 antihypertensives,35 cardiovascular medicines36 
or psychotropics.37 Previous studies have mostly applied 
single cross-sectional study designs.38–46 We found only 
one study that compared results from 2 years, covering a 
7-year period.47 The consistent findings from the previous 
studies are that physicians, pharmacists and package 
leaflets are the most common sources of MI regardless 
of the research method, the study year, the country and 
the research population.21–47 Consumers usually sought 
MI from only one or two information sources.28 34 39 43 44 
The use of the Internet as a source of MI has become 
more common over time, but it is not yet as commonly 
used source of MI for consumers as healthcare profes-
sionals.22 24–26 30 31 33–35 38–40 42 44–46 However, there is a 
lack of long-term population-based studies describing 
trends in the receipt of MI among adult medicine users. 
Repeated surveys are necessary to indicate population 
level changes in the utilisation of available MI sources 
and to reveal needs to develop MI practices and policies 
at the national level. In Finland, improving the accessi-
bility and quality of MI have been among the key stra-
tegic medicines policy goals over the last decades.2 15 The 
long-term comparative information in the receipt of MI 
and the proportion of people receiving MI are important 
measures to indicate whether the desired outcomes are 
met. Therefore, this study examined long-term trends in 




Similar to many developed countries, availability of 
consumer MI has dramatically improved in Finland 
during the last decades.2 4 7 Until 1983, patients and 
medicine users received information about their medi-
cines exclusively from their physicians.7 48 The remark-
able landmarks towards more open access to MI have 
been pharmacists’ duty to counsel on prescription and 
non-prescription medicines in 1983, followed in 1986 by 
the launch of the first computerised database providing 
leaflets for consumers in community pharmacies. Package 
leaflets became mandatory across the European Union 
in 1999.49 About the same time, the Internet and mobile 
phones became more common and eventually revolu-
tionised access to health and MI. ‘From paper the cyber’ 
shift has improved access to statutory MI, for example, 
by making package leaflets available online in written 
and audio format.50 51 A wide range of stakeholders from 
the drug industry to non-profit professional and patient 
organisations have been developing new databases and 
modes for communicating on medicines to consumers. 
To coordinate MI practices and enhance public–private 
partnerships, the European Union has recommended its 
member states to establish national MI programmes and 
strategies.13 Such a strategy was established for the first 
time in Finland in 2012 by the Finnish Medicines Agency.2 
The ultimate goal of the strategy is to improve adherence 
to long-term therapies by enhanced MI by 2020.
study design
The study was conducted as a repeated cross-sectional 
postal survey using each year a new nationally represen-
tative sample (n=5000) of the Finnish adult population 
aged 15–64 years.52 The national health behaviour survey 
used in this study has its origins in the North Karelia 
Project, started in 1972, which has been instrumental in 
improving public health in Finland.53 The annual ‘Health 
Behaviour and Health among the Finnish Adult Popula-
tion’ survey was established in 1978 to perform as an indi-
cator for changes in the population health and related 
risk factors, such as smoking, food and alcohol consump-
tion and physical activity.52 The survey has been targeted 
to the adult working age population of 15–64 years old. 
The survey has been repeated every year in the same way 
to yield comparable results. In addition to the original 
standard set of structured questions, some other questions 
have been added to the survey instrument over the years. 
One of the added questions was the one used in our study 
concerning receipt of MI from different sources available 
for consumers/medicine users in Finland (added to the 
survey instrument in 1999).
The sample has been derived from the Population 
Register Centre of Finland which is a government-based 
register where all Finnish citizens and permanent resi-
dents are obliged to be registered.52 54 The survey has 
been conducted every year (1978–2014) as a postal 
survey.52 The distribution of the questionnaires by mail 
has assured better coverage of the entire study population 
than for example, using online surveys. This is because 
the Population Register Centre has the current address 
available for all Finns and permanent residents. In order 
to maintain response rate high enough for generalis-
able results, three reminders were sent during the study 
period covered in our study (1999–2014).55 Data from the 
years 1999, 2002, 2005 and 2008–2014 were compared as 
these are the years when the survey instrument included 
the question on the receipt of MI.
survey instrument and measures
The main outcome measure was the receipt of MI on 
medicines in use. The survey instrument contained the 
question ‘In the past year (12 months), from which 
sources did you receive information on the medicines 
you have been using?’ The question was followed by a list 
of MI sources available for consumers in Finland at the 
time of the study (figure 1). Respondents could indicate 
from the list as many information sources as applicable. 
It was not possible to report other sources than those 
mentioned in the survey. In 2002, package leaflets and 
telephone services were added to the list of MI sources.
Sociodemographic variables used in this study were 















pen: first published as 10.1136/bm




3Mononen N, et al. BMJ Open 2019;9:e026377. doi:10.1136/bmjopen-2018-026377
Open access
respondents’ medicine use and diagnosed diseases. Use 
of medicines was assessed by the question ‘Have you used 
any tablets, powders or other medicines within the past 
week (7 days)?’ This question was followed by a list of 
commonly used prescription and non-prescription medi-
cines for common chronic and acute conditions (table 1). 
Respondents could indicate from the list as many medi-
cines as they had been using within 7 days prior to the 
survey. It was not possible to report any other medicines 
other than those mentioned in the list. The use of medica-
tion within the past 7 days was used as a measure in order 
to control recall bias.56 Diagnosed diseases were asked by 
a question ‘Within the past year (12 months), have you 
had any of the following diagnosed diseases or diseases 
treated by the physicians?’ This question was followed by 
a list of chronic and acute diseases common in Finland 
(table 1). Respondents could indicate from the list as 
many diseases as they had been suffering from within the 
year prior to the survey. It was not possible to report any 
other diseases than those mentioned in the list.
Analysis
Statistical analyses were conducted with the Statistical 
Package for Social Sciences software (IBM SPSS Statistics 
for Windows V.24.0). Only respondents who reported 
using at least one prescription or non-prescription medi-
cine during the 7 days’ time frame prior to the survey 
were included in the analysis as medicine users.
Age calculation was based on the year of birth, and the 
respondents’ age was divided into five groups. Educa-
tion was measured as the total number of self-reported 
school years and were divided into two educational levels. 
The number of medicines in use was counted for each 
respondent, and respondents were divided into following 
groups: people using one, two, three and four or more 
medicines. Also, the number of diagnosed diseases was 
counted for each respondent, and respondents were 
divided into following groups: no diseases, one, two, 
three or more diseases. The receipt of MI was presented 
by all these medicine user groups and diagnosed diseases. 
The number of MI sources from which the respondents 
had received information on the medicines they used 
was divided into following groups: no sources, one, two, 
three, four, five and six or more sources.
Trends in the receipt of MI from different informa-
tion sources and the number of MI sources used by the 
respondent were counted for each study year 1999, 2002, 
2005 and 2008–2014. The significance of the change in 
the receipt of MI between the study years was analysed 
with logistic regression. Analyses were adjusted for poten-
tial confounding factors (ie, age, gender, educational, 
number of medicines in use and number of diagnosed 
diseases). The receipt of MI from different sources was 
calculated by gender, age, number of medicines in use 
and number of diagnosed diseases for each study year.
Finally, a ratio between the mean number of medi-
cines in use and the mean number of diagnosed diseases 
compared with the mean number of MI sources from 
which MI was received was calculated to indicate whether 
any remarkable changes were seen over time in the 
number of MI sources used in relation to morbidity and 
medicine use.
Patient and public involvement
Patient perspective was taken into account in designing 
the research question on MI by reviewing previous inter-
national and national research on the topic.6 57–59 The 
question as it appears in the survey instrument is a result 
of extensive work by senior researchers in public health 
and medicines information. The question was piloted 
in several formats with the target group (5–10 individ-
uals from the target group recruited as a convenience 
sample) and the current version was found to be most 
valid for the primary purpose of the survey that was to 
indicate long-term trends. The results of the study have 
not been sent to the study participants for comments, but 
the annual reports of the ‘Health Behaviour and Health 
among the Finnish Adult Population’ surveys are  avail-
able online.52 As this study was a secondary analysis using 
routinely collected and fully anonymized data, ethics 
approval was not applicable.60
results
The number of respondents varied by year from 2545 to 
3371, and the response rate decreased from 67% in 1999 to 
53% in 2014 (table 1). Of the total responses (n=29 465), 
64% were from medicine users (n=18 862, ranging by 
year from 58% to 68%). The gender distribution of the 
respondents who reported using medicines remained 
the same throughout the study period, 61%–64% being 
female (table 1). The annual mean age varied between 
41 and 45 years. The respondents used most commonly 
one medicine, ranging from 63% in 1999 to 54% in 
2014 (included prescription and non-prescription medi-
cines). The respondents reported using medicines most 
commonly for headaches (range 50%–53%), other aches 
or pains (28%–31%) and high blood pressure (15%–
23%). More than a third of the medicine users reported 
having at least one diagnosed disease of the diseases 
listed in the survey, increasing from 37% in 1999 to 59% 
in 2014. The most common diseases reported were high 
blood pressure or hypertension (range 18%–25%), high 
blood cholesterol (13%–21%), hay or allergic rhinitis 
(15%–18%) and degenerative disk disease or other back 
illness (13%–15%).
MI sources among adult medicine users
The most commonly reported MI sources were physi-
cians, community pharmacists and package leaflets 
throughout the study period among adult medicine 
users (figure 1 and table 2). These information sources 
were most common despite gender, age, number of 
medicines in use or diagnosed diseases (online supple-
mentary appendices A and B). Receipt of MI from physi-
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decreased most during the study period, while remained 
stable from community pharmacists (46% to 45%) and 
nurses (14% to 14%) (figure 1). In 1999, of the medi-
cine users 17% (n=335/1944) did not report any health-
care professionals (physicians, community pharmacists or 
nurses) as their source of MI, and by 2014 the proportion 
had grown to 38% (n=639/1671). The use of the Internet 
as MI source increased rather steadily being 1% in 1999 
and 16% in 2014.
The number of MI sources from which medicine users 
reported receipt of MI changed over the study period 
1999–2014 (figure 2). The most noticeable decreases 
occurred in those who reported receipt of MI from one 
(47% to 21%) or two (30% to 22%) sources. The number 
of medicine users receiving MI from more than two 
sources increased moderately. In 1999, of the medicine 
users, 4% (n=77/1944) did not report receipt of MI from 
any of the information sources listed in the survey, while 
this proportion had increased to 28% (n=467/1671) in 
2014.
receipt of MI among subgroups
Women reported receiving MI from all information 
sources listed in the survey more commonly than men 
during the study period (online supplementary appendix 
A). Receipt of MI from physicians decreased most among 
women (66% to 48%) and among medicine users aged 
over 45 years (75%–52%). Receipt of MI from package 
leaflets decreased both in women (48% to 38%) and 
men (36% to 26%), while remained nearly unchanged 
from community pharmacists (51% to 47% in women vs 
37% to 42% in men). The receipt of MI from community 
pharmacists increased most among medicine users aged 
55–64 years (34% to 46%), and decreased most among 
medicine users aged 33–44 years (55% to 43%). Package 
leaflets, relatives and friends were reported to be most 
common MI sources for medicine users under 25 years, 
although receipt of MI from package leaflets (59% to 
37%) and from relatives and friends (35% to 16%) 
decreased most in this age group. Receipt of MI from 
the Internet increased in both genders, slightly more in 
women than in men (2% to 18% vs 1% to 12%, respec-
tively), and in all age groups, most among medicine users 
aged 25–34 years (2% to 21%) and 15–24 years (2% to 
20%). More male (6% to 33%) than female (3% to 25%) 
and more medicine users under 45 years (5% to 33%) 
than medicine users 45 years or older (3% to 25%) did 
not report receipt of MI from any of the information 
sources listed in the survey during the study period.
As the number of medicines in use or the number of 
diagnosed diseases increased, the number of different MI 
sources increased (online supplementary appendix B). 
However, the opposite changes occurred in the receipt of MI 
from physicians, the proportion of medicine users receiving 
MI from physicians decreased 14%–26% depending on the 
number of medicines in use or the number of diagnosed 
diseases, the highest decline occurring for medicine users 
with two medicines (76% to 52%) and for medicine users 
with two diagnosed diseases (83% to 57%). The number of 
medicines and the number of diagnosed diseases had the 
opposite influence on the receipt of MI from community 
pharmacists. The receipt of MI from community pharma-
cists increased most in medicine users with three medicines 
Figure 1 Trends in the receipt of medicines information among adult medicine users (n=18 862) in 1999–2014 (% of the 
respondents who reported use of at least one prescription or non-prescription medicine within 7 days prior to the survey). The 
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(47% to 59%) and in those with three or more diagnosed 
diseases (49% to 63%), whereas the receipt of MI decreased 
most in medicine users with one medicine (44% to 38%) 
and in those medicine users without any diagnosed diseases 
(45% to 34%). Receipt of MI package leaflets decreased 
mainly in all medicine users, most in those with one (40% 
to 28%) or two (48% to 35%) medicines in use and in medi-
cine users without any diagnosed diseases (44% to 30%) or 
in those with one diagnosed disease (43% to 31%). Receipt 
of MI from the Internet increased in all medicine users 
regardless of the number of medicines in use or the number 
of diagnosed diseases, most among respondents with two 
(1% to 19%) and four or more medicines (5% to 22%), and 
respondents with three or more diagnosed diseases (3% to 
23%). Respondents using one (6% to 35%) or two (1% to 
24%) medicines and medicine users without any diagnosed 
disease listed in the survey (5% to 38%) or with one disease 
(2% to 25%) most commonly did not report receipt of MI 
from any of the information sources listed in the survey 
during the study period.
Figure 2 Number of medicines information sources from which the adult medicine users (n=18 862) had received information 
on the medicines they used. The survey was not conducted in 2000, 2001, 2003, 2004, 2006 and 2007. 
Figure 3 Ratio between mean number of medicines in use and mean number of diagnosed diseases compared with the mean 
number of medicines information sources from which the medicine users (n=18 862) received medicines information. The survey 
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Overall, the mean number of medicines in use and the 
mean number of diagnosed diseases increased slightly 
among medicine users, while the mean number of MI 
sources from which MI was received remained relatively 
stable during the study period 1999–2014 (figure 3). The 
ratio between the mean number of medicines in use 
and the mean number of MI sources from which MI was 
received remained relatively stable, but the ratio between 
the mean number of diagnosed diseases and the mean 
number of MI sources increased.
DIsCussIOn
To our knowledge, this is the first study analysing long-
term national trends in the receipt of MI among adult 
population. The 15-year period covered in this study 
(1999–2014) provides unique insights into how improved 
consumer access to MI and the shift from paper to cyber 
has influenced receipt of MI from various sources. It 
seems that the key MI sources (physicians, community 
pharmacists and package leaflets) have remained similar 
which is in line with previous studies.21–47 Surprising was 
that even though the availability and the use of MI sources 
has diversified among the adult population, an increasing 
number of medicine users did not report receipt of MI 
from any of the sources.
The proportion of medicine users who did not report 
receiving MI from any of the listed sources became seven-
fold during the study period (4% to 28%). Furthermore, 
the proportion of those who did not report receiving 
MI on medicines they used from any of the healthcare 
professionals more than doubled from 17% in 1999 to 
38% in 2014. Particularly, MI received from the physicians 
declined over time. The decline was similar (22%–26%) 
in respondents using two or more medicines or having 
or not having diagnosed diseases. According to age, 
the decline was most evident among medicine users 45 
years and older. These findings may indicate that physi-
cians are becoming less involved in actual patient care 
as the healthcare has become more fragmented. Thus, 
time allocated for physician office visits has shortened, 
leading to a situation that physicians do not have time 
to concentrate on their patients’ medications.61–64 Conse-
quently, those medicine users who were dependent on MI 
received from their physicians do not have that source 
available anymore. It also seems that community phar-
macists have become more common sources of MI for 
people with multiple medications instead of physicians, 
but nurses have not replaced physicians as a MI source. In 
the future, special attention should be paid to the receipt 
of MI among people with multiple diseases and medi-
cations and the ageing populations whose proportion is 
growing.
Our findings indicate that MI is not evenly distributed 
among medicine users, it may have become more unevenly 
distributed over time. During the study period, women, 
people aged 45 years or older, people with three or more 
medicines in use and people with three or more diagnosed 
diseases received MI more commonly on their medicines 
than other adult medicine users. These findings are in line 
with previous cross-sectional studies.23 25 26 40 41 Other previous 
studies have shown that MI seeking behaviour and the use 
of MI sources is usually influenced by gender and age, but 
also education, ethnic background, income, employment, 
health status and medical history.27 34 39 Potential reasons 
and system-based root causes for differences in the receipt 
of MI among medicine users need to be addressed in future 
research. Our example from Finland demonstrates that 
availability of a wide range of MI sources does not necessarily 
guarantee their actual and evenly distributed use among 
medicine users.
This study indicates that the receipt of MI from the 
Internet was quite rare as more than 90% of the Finns aged 
16–64 years were Internet users in 2014.65 There are no 
similar population-based long-term trend studies from other 
countries to compare our results. According to previous 
studies, use of the Internet as a source of MI has varied 
between 4% and 29% in the 2000s.22 25 31 33 34 39 40 42 44–46 It is 
also known that some patient and medicine user groups use 
the Internet considerably more (59%–68%) than the adult 
population in general, for example, patients with chronic 
conditions and pregnant women.27 28 41 Thus, if we want to 
reach the majority of the adult population, we could not 
solely count on the Internet-based MI sources and services. 
Further population-based research is needed to get a more 
comprehensive understanding of the importance and usage 
patterns of the Internet as a MI source, also the opportuni-
ties it provides for improving MI for various medication user 
segments.
strengths and limitations of this study
As a repeated national population survey, this study allows 
for examination of trends over time at the population level. 
Although the response rate decreased from 67% to 53% 
during the study period, reflecting that the representative-
ness of the results to the entire population is getting weaker, 
it is still adequate for generalisable results.66 67 The non-re-
spondents more often tended to be young men, unmarried 
or single and with a lower level of education.55 Due to the 
cross-sectional method without cohorts, it is not possible 
to follow-up changes in the receipt of MI over time at the 
individual level. The respondents did not have the oppor-
tunity to report MI from other sources than those listed in 
the survey, to report separately MI sources on prescription 
and non-prescription medicines and to distinguish between 
active MI seeking or passive receipt of MI. This should be 
taken account when interpreting results and potential 
implications. For example, the gender difference in the use 
of MI sources may differ depending on whether these are 
discrepancies in the information being provided or gender 
differences in information seeking-behaviours.23 25 26 33 40 41 45 
Furthermore, people using prescription versus non-prescrip-
tion medicines may differ in the amount and use of different 
MI sources. However, in Finland all medicine users should 
receive MI from their healthcare providers while prescribing 
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medicines.68 69 The data did not provide any information 
about the quality, validity or amount of the MI received.
Implications and future research
The strategic development of MI will continue both 
nationally and internationally to ensure the availability 
and access to reliable, up-to-date and high-quality MI 
and MI sources.2 4 13 70 As part of this work, it is neces-
sary to continue research on trends in the receipt of 
MI at the population level and to identify population 
groups needing special attention, such as older adults. 
Consumers’ MI literacy should be further investigated and 
considered in the development of MI for different patient 
and medicine user groups, for example, by including the 
question related to MI literacy in population surveys. The 
present study provides a foundation for further analysis 
that could go deeper in understanding receipt of MI in 
various population groups, changes over time and factors 
influencing it. Further studies are needed also on factors 
contributing to a growing number of medicine users not 
receiving MI from any sources.
COnClusIOns
Healthcare professionals and package leaflets had still 
a dominating importance in 2014 despite the growing 
number of MI sources over time, but still a minority 
of adult medicine users reported receiving MI via the 
Internet in 2014. Worrying is that the proportion of adult 
medicine users who did not receive MI from any of the 
sources became sevenfold during the study period.
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